Literature DB >> 25804996

Comparing the alpha-galactosidase A biochemical properties from healthy individuals and Fabry disease patients.

Vanessa Vitcoski Daitx1, Jamila Mezzalira1, Vitória da Costa Moraes2, Ana Carolina Breier1, Jaqueline Cé1, Janice Carneiro Coelho3.   

Abstract

BACKGROUND: Due to the importance and the difficulty still present in determining the biochemical diagnosis of Fabry disease (FD), the aim of this study was to establish and compare the biochemical and kinetic properties of alpha-galactosidase A (GLA) in dried blood spots (DBS), plasma and leukocyte samples of FD patients and healthy subjects to evaluate the possible use of these parameters as an auxiliary tool in the diagnosis of this disease.
METHODS: GLA activity in DBS, plasma and leukocyte samples from Fabry disease patients and healthy subjects was compared and characterized in terms of optimal pH, Km and Vmax and heat stability.
RESULTS: A difference was observed between the Km and Vmax of FD patients and healthy controls using DBS, plasma and leukocyte samples. In leukocytes, pre-incubation at 50°C for 60 min was effective to differentiate FD patients from healthy controls.
CONCLUSION: These results can be used as an auxiliary method to the FD diagnosis, especially in cases of patients whose GLA activity is within normal range.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha-galactosidase A; Fabry disease; Kinetics; Lysosomal disorders

Mesh:

Substances:

Year:  2015        PMID: 25804996     DOI: 10.1016/j.cca.2015.03.014

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  1 in total

1.  Strong increase of leukocyte apha-galactosidase A activity in two male patients with Fabry disease following oral chaperone therapy.

Authors:  Foudil Lamari; Wladimir Mauhin; Fairouz Koraichi; Walid Khrouf; Celine Bordet; Jonathan London; Olivier Lidove; Philippe Charron
Journal:  Mol Genet Genomic Med       Date:  2019-08-08       Impact factor: 2.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.